Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) has earned an average rating of “Moderate Buy” from the nine research firms that are presently covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $48.10.
Several research analysts have recently weighed in on the stock. Truist Financial assumed coverage on shares of Kymera Therapeutics in a research note on Friday, June 30th. They set a “buy” rating and a $50.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $85.00 price objective on shares of Kymera Therapeutics in a research report on Friday, August 4th. Stifel Nicolaus upped their target price on Kymera Therapeutics from $48.00 to $52.00 and gave the company a “buy” rating in a research report on Monday, August 7th. Credit Suisse Group increased their target price on Kymera Therapeutics from $36.00 to $37.00 and gave the stock a “neutral” rating in a research note on Friday, August 4th. Finally, Morgan Stanley lowered their target price on Kymera Therapeutics from $39.00 to $37.00 and set an “equal weight” rating on the stock in a research note on Tuesday, August 29th.
Get Our Latest Analysis on Kymera Therapeutics
Institutional Inflows and Outflows
Kymera Therapeutics Stock Performance
Shares of KYMR stock opened at $14.88 on Friday. Kymera Therapeutics has a 52-week low of $12.94 and a 52-week high of $39.85. The stock has a market cap of $824.50 million, a PE ratio of -5.39 and a beta of 1.62. The firm’s 50 day moving average price is $18.76 and its two-hundred day moving average price is $24.30.
Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) last announced its quarterly earnings results on Thursday, August 3rd. The company reported ($0.67) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.03. The company had revenue of $16.51 million for the quarter, compared to analysts’ expectations of $13.93 million. Kymera Therapeutics had a negative net margin of 305.01% and a negative return on equity of 33.17%. The business’s quarterly revenue was up 43.4% compared to the same quarter last year. During the same period last year, the firm posted ($0.78) earnings per share. As a group, sell-side analysts predict that Kymera Therapeutics will post -2.55 earnings per share for the current fiscal year.
About Kymera Therapeutics
Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
Read More
- Five stocks we like better than Kymera Therapeutics
- Most Volatile Stocks, What Investors Need to Know
- How To Find Value Stocks Using This Simple Filtering Method
- Your Comprehensive Guide to Investing in Bank Stocks
- MarketBeat Week in Review – 10/2 – 10/6
- How to Calculate Stock Profit
- Levi Strauss: A Bottom is in for Steady, Stable Dividend Payer
Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
